Prostate‐specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time

To compare the accuracy of prostate‐specific antigen (PSA) velocity (PSAV) vs PSA doubling time (DT) for predicting the repeat biopsy results in men with localized prostate cancer on active surveillance (AS), as the utility of PSAV vs PSADT in untreated prostate cancer has not been well studied.

[1]  L. Holmberg,et al.  Prostate-specific antigen levels as a predictor of lethal prostate cancer. , 2007, Journal of the National Cancer Institute.

[2]  Alan Horwich,et al.  Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. , 2008, European urology.

[3]  Rosalie Nolley,et al.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? , 2004, The Journal of urology.

[4]  Gurkamal Chatta,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy , 2003 .

[5]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[6]  P. Walsh,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.

[7]  D. Chan,et al.  Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. , 1992, Cancer research.

[8]  J. Gohagan,et al.  Prostate‐specific antigen velocity and prostate cancer gleason grade and stage , 2007, Cancer.

[9]  A. Renshaw,et al.  Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Daskivich,et al.  Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. , 2006, The Journal of urology.

[11]  A. D'Amico,et al.  Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Ferrucci,et al.  PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. , 2008, European urology.

[13]  Ming-Hui Chen,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.

[14]  E. Rakovitch,et al.  PSA doubling time of prostate carcinoma managed with watchful observation alone. , 2001, International journal of radiation oncology, biology, physics.

[15]  D. Dearnaley,et al.  Predictors of histological disease progression in untreated, localized prostate cancer. , 2007, The Journal of urology.

[16]  M. Terris,et al.  Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. , 2007, Urology.

[17]  T. H. van der Kwast,et al.  Does PSA velocity predict prostate cancer in pre-screened populations? , 2006, European urology.

[18]  A. Worster,et al.  Understanding receiver operating characteristic (ROC) curves. , 2006, CJEM.

[19]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[20]  S. Freedland,et al.  Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. , 2001, Urology.

[21]  Lurdes Y. T. Inoue,et al.  Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. , 2007, Journal of the National Cancer Institute.

[22]  William J Catalona,et al.  Prostate-specific antigen in clinical practice. , 2007, Cancer letters.

[23]  L. Bégin,et al.  Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. , 2002, Urology.

[24]  M. Blute,et al.  Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. , 2005, The Journal of urology.

[25]  Ming-Hui Chen,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.